BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 33890815)

  • 1. Clinicopathological Follow-up of Breast DCIS Diagnosed on Biopsies: A Single Institutional Study of 575 Patients.
    Yan M; Bomeisl P; Gilmore H; Harbhajanka A
    Int J Surg Pathol; 2021 Dec; 29(8):836-843. PubMed ID: 33890815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Sentinel Lymph Node Biopsy and Factors Associated with Invasion in Extensive DCIS of the Breast Treated by Mastectomy: The Cinnamome Prospective Multicenter Study.
    Tunon-de-Lara C; Chauvet MP; Baranzelli MC; Baron M; Piquenot J; Le-Bouédec G; Penault-Llorca F; Garbay JR; Blanchot J; Mollard J; Maisongrosse V; Mathoulin-Pélissier S; MacGrogan G
    Ann Surg Oncol; 2015 Nov; 22(12):3853-60. PubMed ID: 25777085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in ductal carcinoma in situ (DCIS) and DCIS with microinvasion.
    Wan ZB; Gao HY; Wei L; Zhang AQ; Zhang JY; Wang Y; Wang DD; Zhang Y
    Medicine (Baltimore); 2018 Nov; 97(44):e13055. PubMed ID: 30383678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axillary evaluation is not warranted in patients preoperatively diagnosed with ductal carcinoma in situ by core needle biopsy.
    Si J; Guo R; Huang N; Xiu B; Zhang Q; Chi W; Wu J
    Cancer Med; 2019 Dec; 8(18):7586-7593. PubMed ID: 31660702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United States $35 Million/y.
    VandenBussche CJ; Cimino-Mathews A; Park BH; Emens LA; Tsangaris TN; Argani P
    Am J Surg Pathol; 2016 Aug; 40(8):1090-9. PubMed ID: 27299796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors predicting microinvasion in Ductal Carcinoma in situ.
    Ozkan-Gurdal S; Cabioglu N; Ozcinar B; Muslumanoglu M; Ozmen V; Kecer M; Yavuz E; Igci A
    Asian Pac J Cancer Prev; 2014; 15(1):55-60. PubMed ID: 24528005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases.
    Yang M; Moriya T; Oguma M; De La Cruz C; Endoh M; Ishida T; Hirakawa H; Orita Y; Ohuchi N; Sasano H
    Pathol Int; 2003 Jul; 53(7):422-8. PubMed ID: 12828606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ductal carcinoma in situ: value of sentinel lymph node biopsy.
    Sakr R; Barranger E; Antoine M; Prugnolle H; Daraï E; Uzan S
    J Surg Oncol; 2006 Oct; 94(5):426-30. PubMed ID: 16967457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2-Overexpressing Ductal Carcinoma
    O'Keefe TJ; Blair SL; Hosseini A; Harismendy O; Wallace AM
    Cancer Prev Res (Phila); 2020 Sep; 13(9):761-772. PubMed ID: 32493703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variations in the management of the axilla in screen-detected ductal carcinoma in situ: evidence from the UK NHS breast screening programme audit of screen detected DCIS.
    Nicholson S; Hanby A; Clements K; Kearins O; Lawrence G; Dodwell D; Bishop H; Thompson A;
    Eur J Surg Oncol; 2015 Jan; 41(1):86-93. PubMed ID: 25441934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
    Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
    Halasz LM; Sreedhara M; Chen YH; Bellon JR; Punglia RS; Wong JS; Harris JR; Brock JE
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e581-6. PubMed ID: 22208975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit.
    Moore KH; Sweeney KJ; Wilson ME; Goldberg JI; Buchanan CL; Tan LK; Liberman L; Turner RR; Lagios MD; Cody Iii HS; Giuliano AE; Silverstein MJ; Van Zee KJ
    Ann Surg Oncol; 2007 Oct; 14(10):2911-7. PubMed ID: 17597346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer.
    Mustafa RE; DeStefano LM; Bahng J; Yoon-Flannery K; Fisher CS; Zhang PJ; Tchou J; Czerniecki BJ; De La Cruz LM
    Ann Surg Oncol; 2017 Oct; 24(10):2999-3003. PubMed ID: 28766212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological underestimation and biomarkers concordance rates in breast cancer patients diagnosed with ductal carcinoma in situ at preoperative biopsy.
    Zhou H; Yu J; Wang X; Shen K; Ye J; Chen X
    Sci Rep; 2022 Feb; 12(1):2169. PubMed ID: 35140303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk predictors of underestimation and the need for sentinel node biopsy in patients diagnosed with ductal carcinoma in situ by preoperative needle biopsy.
    Park HS; Park S; Cho J; Park JM; Kim SI; Park BW
    J Surg Oncol; 2013 Mar; 107(4):388-92. PubMed ID: 23007901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sentinel lymph node biopsy is not necessary in patients diagnosed with ductal carcinoma in situ of the breast by stereotactic vacuum-assisted biopsy.
    Kotani H; Yoshimura A; Adachi Y; Ishiguro J; Hisada T; Ichikawa M; Gondou N; Hattori M; Kondou N; Sawaki M; Fujita T; Iwata H
    Breast Cancer; 2016 Mar; 23(2):190-4. PubMed ID: 24989112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Emerging Roles of Steroid Hormone Receptors in Ductal Carcinoma in Situ (DCIS) of the Breast.
    Villanueva H; Grimm S; Dhamne S; Rajapakshe K; Visbal A; Davis CM; Ehli EA; Hartig SM; Coarfa C; Edwards DP
    J Mammary Gland Biol Neoplasia; 2018 Dec; 23(4):237-248. PubMed ID: 30338425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
    Margalit DN; Sreedhara M; Chen YH; Catalano PJ; Nguyen PL; Golshan M; Overmoyer BA; Harris JR; Brock JE
    Ann Surg Oncol; 2013 Mar; 20(3):811-8. PubMed ID: 22956068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Necessity of sentinel lymph node biopsy in ductal carcinoma in situ patients: a retrospective analysis.
    Shin YD; Lee HM; Choi YJ
    BMC Surg; 2021 Mar; 21(1):159. PubMed ID: 33752671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.